Unique ID issued by UMIN | UMIN000015352 |
---|---|
Receipt number | R000017848 |
Scientific Title | A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome |
Date of disclosure of the study information | 2014/10/07 |
Last modified on | 2018/06/29 20:13:09 |
A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome
Effects of probiotic LKM512 and arginine on function of vascular endothelium
A randamized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in individuals with pre-metabolic syndrome
Effects of probiotic LKM512 and arginine on function of vascular endothelium
Japan |
pre-metabolic syndrome
Medicine in general |
Others
NO
To evaluate the efficacy of oral administration of probiotic LKM512 and arginine on function of vascular endothelium in patients with pre-metabolic syndrome
Efficacy
RH-PAT(Endo-PAT)
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
The volunteer were given an 8-week treatment with oral administration of bifidobacteria LKM512 powder (6 billion bacterial cells/stick) and 3 arginine tablets (100mg/tablet) two times per day.
The volunteer were given an 8-week treatment with oral administration of placebo powder without bifidobacteria LKM512 and 3 placebo tablets without arginine two times per day.
40 | years-old | <= |
75 | years-old | > |
Male and Female
Outpatients whose BMl is more than 25.0
1. Outpatients whose BMl is more than 25.0
2. Subjects who take a medicine for dyslipidemia treatment
3. Serious subjects who have complications with cardiac disease, hepatic disease,and/or renal disease
4. Subjects who had serious gastrointestinal disease in the past
5. Subjects who take hypotensive medicines
6. Subjects who have serious constipation
7. Subjects who was enrolled in other trails within one month
8. Inappropriate cases evaluated by doctors
40
1st name | |
Middle name | |
Last name | Mitsuharu Matsumoto |
Kyodo Milk Industry Co. Ltd.
Research Laboratories
20-1 Hirai, Hinode-machi, Nishitama-gun, Tokyo 190-0182
042-597-5911
m-matumoto@meito.co.jp
1st name | |
Middle name | |
Last name | Satoshi Sakurai |
imeQ CO. Ltd.
CRO division
a vous primus Bld, 2-14-6, nishiwaseda, Shinjuku-ku, Tokyo 169-0075
03-6279-3591
s-sakurai@imeq.co.jp
Kyodo Milk Industry Co. Ltd.
Kyodo Milk Industry Co. Ltd.
Profit organization
NO
医療法人社団 札幌百合の会病院 (北海道)
2014 | Year | 10 | Month | 07 | Day |
Unpublished
Completed
2014 | Year | 09 | Month | 11 | Day |
2014 | Year | 10 | Month | 07 | Day |
2014 | Year | 10 | Month | 06 | Day |
2018 | Year | 06 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017848
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |